Answers are grounded in this paper and cite their sources.
The distinction between radiation necrosis (RN) and local recurrence (LR) after stereotactic radiosurgery (SRS) has never been more critical: the growing number of long‑term survivors and the increasingly widespread use of radiosurgery are multiplying the cases of enlarging lesions with uncertain etiology, making an updated clarification of clinical and dosimetric criteria essential. SRS has become a mainstay in the treatment of brain metastases, providing excellent local control while limiting neurocognitive toxicity compared with whole‑brain radiotherapy. However, as more patients are treated, radiographic post‑treatment changes have correspondingly increased, and they remain difficult to interpret even with advanced imaging. Despite progress in advanced MRI, amino‑acid PET, and radiomics, biopsy remains the reference standard, an invasive solution that is not always feasible. In this issue of Neuro‑Oncology Practice, Gonzalez et al1 offer one of the broadest and most robust contributions to date to identify clinical and dosimetric factors associated with RN versus LR. Their retrospective analysis of 151 progressive lesions with histologic confirmation represents one of the largest available cohorts. The authors identify age ≥65 years, SRS‑to‑biopsy interval ≥9 months, and higher V12Gy as independent predictors of RN. These results confirm and strengthen previous observations while providing a more robust predictive framework for clinical practice.
No takes yet. Share an insight, caveat, or question.
Pontoriero et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: